Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Revenue projections:

Revenue projections for JUBLPHARMA
Revenue projections for JUBLPHARMA

With JUBLPHARMA's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 1.65300
forwardPE 23.38843
debtToEquity 43.77600
earningsGrowth 0.00000
revenueGrowth 0.09700
grossMargins 0.67973
operatingMargins 0.12972
trailingEps 52.80000
forwardEps 0.00000

JUBLPHARMA's current ratio, being 1.653, means the company is well-positioned to meet its short-term debt obligations. This reflects JUBLPHARMA's strong liquidity, as its cash reserves and current assets provide more than enough coverage for its immediate liabilities.
JUBLPHARMA's Forward PE is positioned well, reflecting a favorable balance between stock price and earnings. The stock isn't overpriced, offering room for growth and making it a potentially rewarding investment as its value has room to rise further.

Price projections:

Price projections for JUBLPHARMA
Price projections for JUBLPHARMA

The current price of Jubilant Pharmova Limited, when assessed against projections, reveals no significant risks or opportunities. This situation indicates a steady market environment, prompting investors to remain patient until more clarity emerges regarding the stock's potential.

Insider Transactions:

Insider Transactions for JUBLPHARMA
Insider Transactions for JUBLPHARMA


There were 1 purchases of JUBLPHARMA stock, with market price of 1219.5999755859375.There were no buy transactions throughout the period under consideration.Jubilant Pharmova Limited has seen more sells than buys at current price levels, which could point to a potential price drop. If this selling trend persists, it may indicate that investors are expecting further declines in the stock's value.

Recommendation changes over time:

Recommendations trend for JUBLPHARMA
Recommendations trend for JUBLPHARMA


Analysts' buy bias toward JUBLPHARMA suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, JUBLPHARMA is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.